Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Dreicer

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|July 8, 2020
New mitomycin formulation for low-grade upper tract urothelial cancerRobert Dreicer
Journal of Surgical Oncology|April 11, 2012
Systemic therapy for advanced adrenal cancerRobert Dreicer
Urology|December 17, 2013
Editorial commentRobert Dreicer
The Lancet. Oncology|October 3, 2017
New option for cisplatin-ineligible urothelial cancerRobert Dreicer
Urology|August 28, 2019
EDITORIAL COMMENTRobert Dreicer
Urology|January 30, 2017
Editorial CommentRobert Dreicer
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancerRobert Dreicer
Cancer Treatment Reviews|October 5, 2002
Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomyRobert Dreicer
The Canadian Journal of Urology|April 30, 2014
How to approach sequencing therapy in patients with metastatic castration resistant prostate cancerRobert Dreicer
The Journal of Supportive Oncology|November 20, 2010
Androgen deprivation therapy in patients with advanced prostate cancerRobert Dreicer
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|July 8, 2020
New mitomycin formulation for low-grade upper tract urothelial cancerRobert Dreicer
Journal of Surgical Oncology|April 11, 2012
Systemic therapy for advanced adrenal cancerRobert Dreicer
Urology|December 17, 2013
Editorial commentRobert Dreicer
The Lancet. Oncology|October 3, 2017
New option for cisplatin-ineligible urothelial cancerRobert Dreicer
Urology|August 28, 2019
EDITORIAL COMMENTRobert Dreicer
Urology|January 30, 2017
Editorial CommentRobert Dreicer
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancerRobert Dreicer
Cancer Treatment Reviews|October 5, 2002
Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomyRobert Dreicer
The Canadian Journal of Urology|April 30, 2014
How to approach sequencing therapy in patients with metastatic castration resistant prostate cancerRobert Dreicer
The Journal of Supportive Oncology|November 20, 2010
Androgen deprivation therapy in patients with advanced prostate cancerRobert Dreicer
Pageof 21